In this preliminary analysis of data released from a large clinical trial of sibutramine (Meridia), participants randomized to sibutramine had higher rates of cardiovascular events (MI, CVA, cardiac arrest, or death) than those randomized to placebo (11.4% vs 10%). The FDA recommends patients with a history of CAD, CHF, CVA, or arrythmias not be prescribed sibutramine (FDA site)

This entry was posted on Monday, November 23rd, 2009 at 1:07 pm and is filed under Cardiology. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.